GSK Outperforms Expectations with Strong Q2 Sales
GSK is set to achieve the upper end of its sales and profit forecasts for the year, driven by better-than-expected second-quarter results. Focused on expanding its drug pipeline, the company remains resilient amid tariff challenges. CEO Walmsley highlighted growth in specialty medicines, boosting overall performance.
British pharmaceutical company GSK is positioning itself for a strong year, predicting annual sales and profits at the top of its forecast range after surpassing expectations in the second quarter. The company's success is largely attributed to its focus on expanding its drug pipeline, especially in infectious diseases, to offset slowing demand and increasing competition.
Despite the potential impacts of tariffs introduced under a new European Union-U.S. trade deal, which imposes a 15% tariff on goods including pharmaceuticals, GSK remains confident it can navigate these financial pressures. The company has projected a revenue increase of 3% to 5% by 2025, with core profit growth per share expected to be between 6% and 8%.
GSK CEO Emma Walmsley shared in a statement that the firm's robust performance in specialty medicines, particularly in areas such as respiratory, immunology, inflammation, oncology, and HIV, has been a key driver of its success, achieving double-digit sales growth. Turnover rose 6% on constant currency rates, reaching nearly 8 billion pounds, with adjusted earnings per share at 46.5 pence, surpassing analysts' expectations.
(With inputs from agencies.)
Google News